Product Description
ABL(T315I) is a highly prevalent resistance mutation in ABL1, a non‑receptor tyrosine kinase that plays essential roles in cell proliferation, survival, and adhesion. In the context of the BCR‑ABL1 fusion oncoprotein—the primary driver of chronic myeloid leukemia (CML) and Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL)—the T315I mutation occurs within the kinase domain at the “gatekeeper” residue. This substitution disrupts the critical hydrogen bond required for binding of most ATP‑competitive tyrosine kinase inhibitors, including imatinib, dasatinib, nilotinib, and bosutinib, while preserving the active conformation of the kinase. As a result, T315I confers broad resistance to all approved first‑ and second‑generation inhibitors, rendering it one of the most challenging clinical obstacles in targeted leukemia therapy. Its emergence is closely associated with disease progression and treatment failure, making it a compelling target for third‑generation inhibitors such as ponatinib and for next‑generation therapeutic strategies in precision oncology.
Screeningbio’s ABL(T315I) Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying ABL(T315I) kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: ABL(T315I) catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the ABL(T315I) kinase.
Data